Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ironwood Pharmaceuticals, Inc. - Class A Common Stock (NQ:IRWD)

0.7660 +0.0263 (+3.56%)
Streaming Delayed Price Updated: 1:00 PM EDT, Jul 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ironwood Pharmaceuticals, Inc. - Class A Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Ironwood Pharmaceuticals Initiates Apraglutide NDA Submission, Highlights Compelling New Data and Updates Corporate Structure to Position for the Future
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Ironwood Pharmaceuticals to Participate in the Piper Sandler 36th Annual Healthcare Conference
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Ironwood Pharmaceuticals to Participate in the Jefferies London Healthcare Conference
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Earnings Preview: Ironwood Pharmaceuticals
Via Benzinga
Ironwood Pharmaceuticals Reports Third Quarter 2024 Results
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Once-Weekly Apraglutide Showed Consistent Treatment Effect Across Baseline Demographics and Disease Characteristics in Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF), According to New STARS Phase III Data from Ironwood at ACG 2024
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Ironwood Pharmaceuticals to Host Third Quarter 2024 Investor Update Call
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Ironwood Pharmaceuticals to Participate in the 2024 Wells Fargo Healthcare Conference
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
IRWD Stock Earnings: Ironwood Pharmaceuticals Misses EPS, Misses Revenue for Q2 2024
IRWD stock results show that Ironwood Pharmaceuticals missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. 
Via InvestorPlace
Ironwood Pharmaceuticals Reports Second Quarter 2024 Results
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Ironwood Pharmaceuticals to Host Second Quarter 2024 Investor Update Call
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Asana, Clover Health Investments, Hertz Global And Other Big Stocks Moving Higher On Friday
Via Benzinga
Ironwood Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Ironwood Late-Breaker Oral Presentation at Digestive Disease Week® Reinforces Potential of Once-Weekly Apraglutide for Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF)
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Why Duolingo Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
IRWD Stock Earnings: Ironwood Pharmaceuticals Misses EPS, Misses Revenue for Q1 2024
IRWD stock results show that Ironwood Pharmaceuticals missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Ironwood Pharmaceuticals Reports First Quarter 2024 Results
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Ironwood Pharmaceuticals to Participate in The Citizens JMP Life Sciences Conference
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Ironwood Pharmaceuticals to Present New Data on Once-Weekly Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF) at Digestive Disease Week® 2024
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Stock Market Crash Warning: Don’t Get Caught Holding These 3 Biotech Stocks
As the stock market corrects, focusing on stable investments is crucial. This is why you should steer clear of these biotech stocks to avoid. 
Via InvestorPlace
Ironwood Pharmaceuticals to Host First Quarter 2024 Investor Update Call
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Ironwood Pharmaceuticals Announces Positive Results from its Phase II Exploratory STARGAZE Trial of Apraglutide in Patients with Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease (SR GI aGVHD)
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In March
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. 
Via Benzinga
It’s Time! 3 Failing Biotech Stocks to Sell Right Now
The biotech industry offers investors unique investment opportunities but these three are biotechs to sell. 
Via InvestorPlace
Why Butterfly Network Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of Butterfly Network, Inc. (NASDAQ: BFLY) fell sharply during Thursday’s session after the company reported mixed fourth-quarter financial results. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Stocks Mixed, Headed For Monthly Wins
In what appears to be a theme this week, stocks are hesitant midday as investors unpack this morning's jobs and inflation data. 
Via Talk Markets
Topics Economy
Why Is Gastrointestinal Healthcare Focused Ironwood Pharmaceuticals Stock Sinking On Thursday?
Ironwood Pharmaceuticals' SBS-IF treatment Apraglutide's Phase 3 trial met primary endpoints, reducing PS dependency by 25.5% vs. placebo, but misses on two key secondary endpoints. 
Via Benzinga
Nasdaq Gains 100 Points Following PCE Data
U.S. stocks traded mostly higher this morning, with the Nasdaq Composite gaining around 100 points on Thursday. Following the market opening Thursday, the Dow traded down 0.07% to 38,923.11 while the... 
Via Benzinga
Topics Stocks
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.